Hemophagocytic Lymphohistiocytosis Clinical Trial
Official title:
L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV Associated Hemophagocytic Lymphohistiocytosis (HLH)
This study aimed to investigate the efficacy and safety of L-DEP (L-Asparaginasum, liposomal doxorubicin, etoposide and methylprednisolone) together with PD-1 antibody as an treatment for relapse/refractory EBV associated hemophagocytic lymphohistiocytosis.
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | June 1, 2026 |
Est. primary completion date | June 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year to 70 Years |
Eligibility | Inclusion Criteria: 1. Meet hemophagocytic lymphohistiocytosis (HLH)-04 diagnostic criteria;patients were diagnosed with EBV associated HLH (EBV-HLH). 2. EBV-DNA in peripheral blood or EBER in tissue were positive. 3. Treated with HLH-94 no less than 2 weeks before enrollment and did not achieve at least partial response 4. The patient is expected to be unable to undergo allogeneic hematopoietic stem cell transplantation in the short term due to various reasons (physical status, economic reasons, donor reasons, etc.) 5. The expected survival time is more than 1 month. 6. Age = years old, gender is not limited. 7. Serum creatinine = 1.5 times normal;After infusion, fibrinogen can be corrected to =0.6g/L. 8. Serum human immunodeficiency virus(HIV) antigen or antibody negative; Hepatitis C virus (HCV) antibody is negative, or HCV antibody is positive, but HCV RNA is negative;HBV copies less than 1E+03 copies/ml. 9. The left ventricular ejection fraction (LVEF) was normal. 10. No uncontrollable infection. 11. Contraception for both male or female. 12. Informed consent obtained. Exclusion Criteria: 1. Allergic to doxorubicin and/or etoposide and/or PD-1 antibody Injection 2. Severe myocardial injury, myocardial enzymes CK, CK-MB increased more than 3 times ULN (upper limit of normal) 3. Heart function above grade II (NYHA). 4. Thyroid dysfunction 5. Serious mental illness; 6. Active hemorrhage of internal organs 7. Previously received L-DEP regimen for HLH-targeted treatment, but the treatment was ineffective or relapsed 8. Accumulated dose of doxorubicin above 300mg/m2 or epirubicin above 450mg/m2 9. Participate in other clinical research at the same time. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Friendship Hospital, Capital Medical University | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing Friendship Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of treatment response | The primary observed endpoint is the objective remission rate (ORR): cases that include complete remission (CR) and partial remission (PR).CR was defined as normalization of all of the quantifiable symptoms and laboratory markers of HLH, including levels of sCD25, ferritin, and triglyceride; hemoglobin; neutrophil counts; platelet counts; and alanine aminotransferase (ALT). PR was defined as at least a 25% improvement in 2 or more quantifiable symptoms and laboratory markers as follows: sCD25 response was>1.5-fold decreased; ferritin and triglyceride decreased at least 25%; for patients with an initial neutrophil count of<0.5 ×109/L, a response was defined as an increase by at least 100% to>0.5× 109/L; for patients with a neutrophil count of 0.5 to 2.0 × 109/L, an increase by at least 100% to >2.0 × 109/L was considered a response; and for patients with ALT >400 U/L, response was defined as an ALT decrease of at least 50%. | Change from before and 2,4,6 and 8 weeks after initiating DEP combine with PD-1 antibody therapy | |
Secondary | EBV-DNA | Outcome of patients with EBV-HLH | Change from before and 2,4,6 and 8 weeks after initiating DEP combine with PD-1 antibody therapy | |
Secondary | Survival | Outcome of patients with EBV-HLH | 3 months after the intervention | |
Secondary | Adverse events that are related to treatment | Incidence of events that are related to treatment including myelosuppression, infection, bleeding and so on. | 2,4,6 and 8 weeks after initiating DEP combine with PD-1 antibody therapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01652092 -
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
|
N/A | |
Recruiting |
NCT02912702 -
L-DEP as an Initial Treatment for EBV-HLH
|
Phase 3 | |
Terminated |
NCT00176826 -
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06038422 -
GTP Regimen in the Treatment of Refractory/Recurrent HLH
|
Phase 3 | |
Completed |
NCT03510650 -
Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)
|
||
Completed |
NCT03259230 -
Study to Evaluate Interferon Gamma (IFNγ) and Other Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH)
|
||
Active, not recruiting |
NCT01494103 -
Administration of Donor T Cells With the Caspase-9 Suicide Gene
|
Phase 1 | |
Recruiting |
NCT05164978 -
DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH
|
N/A | |
Recruiting |
NCT01821781 -
Immune Disorder HSCT Protocol
|
Phase 2 | |
Terminated |
NCT01547143 -
Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis
|
N/A | |
Active, not recruiting |
NCT00006056 -
Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
|
N/A | |
Terminated |
NCT00006054 -
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
|
N/A | |
Recruiting |
NCT03795909 -
Ruxolitinib Combined With Dexamethasone for HLH
|
Phase 1/Phase 2 | |
Recruiting |
NCT03533790 -
DEP-Ru Regimen as a Salvage Therapy for HLH
|
Phase 3 | |
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Recruiting |
NCT04326348 -
A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis(HLH)
|
Phase 1 | |
Recruiting |
NCT04551131 -
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT05546060 -
Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH
|
Phase 1 | |
Recruiting |
NCT05137522 -
Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH
|
N/A | |
Recruiting |
NCT04120090 -
Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis
|
Phase 3 |